These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18413806)

  • 1. SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
    Cao X; Clavijo C; Li X; Lin HH; Chen Y; Shih HM; Ann DK
    Mol Cancer Ther; 2008 Apr; 7(4):923-34. PubMed ID: 18413806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
    Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
    PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
    Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
    J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
    Fasci D; Anania VG; Lill JR; Salvesen GS
    Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
    Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
    Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
    Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
    Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
    Rabellino A; Carter B; Konstantinidou G; Wu SY; Rimessi A; Byers LA; Heymach JV; Girard L; Chiang CM; Teruya-Feldstein J; Scaglioni PP
    Cancer Res; 2012 May; 72(9):2275-84. PubMed ID: 22406621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
    Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
    Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
    Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies.
    Geoffroy MC; Jaffray EG; Walker KJ; Hay RT
    Mol Biol Cell; 2010 Dec; 21(23):4227-39. PubMed ID: 20943951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation.
    Saito Â; Souza EE; Costa FC; Meirelles GV; Gonçalves KA; Santos MT; Bressan GC; McComb ME; Costello CE; Whelan SA; Kobarg J
    J Proteome Res; 2017 Sep; 16(9):3147-3157. PubMed ID: 28695742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
    Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
    J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
    Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
    Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
    Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
    Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Ubiquitin-like Modifier Alters IFN Response.
    Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
    J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins.
    Sahin U; Ferhi O; Jeanne M; Benhenda S; Berthier C; Jollivet F; Niwa-Kawakita M; Faklaris O; Setterblad N; de Thé H; Lallemand-Breitenbach V
    J Cell Biol; 2014 Mar; 204(6):931-45. PubMed ID: 24637324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.
    Gao C; Ho CC; Reineke E; Lam M; Cheng X; Stanya KJ; Liu Y; Chakraborty S; Shih HM; Kao HY
    Mol Cell Biol; 2008 Sep; 28(18):5658-67. PubMed ID: 18625722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.
    Dassouki Z; Sahin U; El Hajj H; Jollivet F; Kfoury Y; Lallemand-Breitenbach V; Hermine O; de Thé H; Bazarbachi A
    Blood; 2015 Jan; 125(3):474-82. PubMed ID: 25395419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator.
    Karvonen U; Jääskeläinen T; Rytinki M; Kaikkonen S; Palvimo JJ
    J Mol Biol; 2008 Oct; 382(3):585-600. PubMed ID: 18656483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.